Study of 18F-Fluciclovine PET Imaging to Evaluate Surgery and Recurrence in Brain Metastasis Patients Using Stereotactic Radiosurgery After Tumor Removal

What this Trial Is About

Researchers are studying patients who have undergone surgery to remove brain metastases and are scheduled for stereotactic radiosurgery SRS afterward. The study aims to evaluate whether the imaging agent 18F-Fluciclovine, used alongside MRI, can better detect residual tumor tissue and identify recurrent disease that MRI alone might miss. This agent is investigational for imaging brain metastases. Participants will receive a 5-mCi dose of 18F-Fluciclovine through an intravenous injection after fasting for at least four hours. The PETCT scan using this agent will be performed at the time of SRS treatment, about 2 to 4 weeks after surgery, alongside the standard MRI. Patients will continue to have combined 18F-Fluciclovine PETCT and MRI scans during routine follow-ups to monitor tumor control, detect recurrence, and assess areas at risk. During the study, participants will undergo PETCT imaging sessions with 18F-Fluciclovine and MRI scans at baseline and at 3 weeks, 6 months, and 12 months. Researchers will measure changes in tumor volume delineation and PET scan uptake values to assess treatment response. Safety and tumor control will also be monitored, with follow-up assessments extending to at least one year. The total study duration varies by participant based on follow-up timing.

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis